Brii Biosciences Limited (DE:7SS)
FRANKFURT:7SS
7SS Stock Chart & Stats
€0.19
<€0.01(7.63%)
At close: 4:00 PM EST
€0.19
<€0.01(7.63%)
Day’s Range― - ―
52-Week Range€0.11 - €0.26
Previous CloseN/A
Volume0.00
Average Volume (3M)248.00
Market Cap
€88.11M
Enterprise Value€116.66M
Total Cash (Recent Filing)€1.94B
Total Debt (Recent Filing)€8.93M
Price to Earnings (P/E)―
Beta1.20
Next Earnings
Aug 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.30
Shares Outstanding734,530,500
10 Day Avg. Volume8
30 Day Avg. Volume248
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)0.38
Price to Sales (P/S)50.44
P/FCF Ratio-3.17
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.02
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Strong Balance SheetA very low debt load and sizable positive equity provide durable financial flexibility for a biotech firm. This reduces refinancing risk, supports funding of clinical and commercial activities through uneven cash flows, and cushions the company during long R&D timelines.
Partnering / Commercialization Business ModelA model combining in-licensing, commercialization, licensing fees, milestones and royalties spreads development risk and creates multiple revenue levers. Durable partnerships can fund R&D and provide non-dilutive cash inflection points as candidates progress or get commercialized.
Improving Cash Burn Trend In 2025A reduction in cash burn year-over-year signals management is improving cost structure or resource allocation. If sustained, this trend lengthens runway, lowers future funding frequency, and increases the odds of reaching value-inflecting regulatory or commercial milestones.
Bears Say
Persistent Operating LossesOngoing, deep operating losses indicate the business has not reached scalable, self-sustaining operations. Persistent negative margins erode equity over time, require continued external funding, and make it harder to achieve durable profitability even if revenues stabilize.
Consistent Negative Cash FlowChronic negative operating and free cash flow creates structural dependence on new financing or partner payments. This constrains reinvestment into R&D and commercialization, increases dilution or leverage risk, and raises execution risk for multi-year development programs.
Sharp Revenue Contraction And VolatilityA material, recent decline in revenue undermines commercial momentum and predictability of milestone/royalty streams. Revenue volatility makes planning and scaling difficult, reduces operating leverage, and weakens the firm's ability to fund pipeline advancement from internal cash flows.
Brii Biosciences Limited News
7SS FAQ
What was Brii Biosciences Limited’s price range in the past 12 months?
Brii Biosciences Limited lowest stock price was €0.11 and its highest was €0.26 in the past 12 months.
What is Brii Biosciences Limited’s market cap?
Brii Biosciences Limited’s market cap is €88.11M.
When is Brii Biosciences Limited’s upcoming earnings report date?
Brii Biosciences Limited’s upcoming earnings report date is Aug 20, 2026 which is in 76 days.
How were Brii Biosciences Limited’s earnings last quarter?
Brii Biosciences Limited released its earnings results on Mar 19, 2026. The company reported -€0.004 earnings per share for the quarter, beating the consensus estimate of -€0.008 by €0.004.
Is Brii Biosciences Limited overvalued?
According to Wall Street analysts Brii Biosciences Limited’s price is currently Overvalued.
Does Brii Biosciences Limited pay dividends?
Brii Biosciences Limited does not currently pay dividends.
What is Brii Biosciences Limited’s EPS estimate?
Brii Biosciences Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Brii Biosciences Limited have?
Brii Biosciences Limited has 734,530,500 shares outstanding.
What happened to Brii Biosciences Limited’s price movement after its last earnings report?
Brii Biosciences Limited reported an EPS of -€0.004 in its last earnings report, beating expectations of -€0.008. Following the earnings report the stock price went down -4.43%.
Which hedge fund is a major shareholder of Brii Biosciences Limited?
Currently, no hedge funds are holding shares in DE:7SS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Brii Biosciences Limited
Brii Biosciences Limited engages in the development of medicines for the treatment of infectious and central nervous system diseases. The company develops BRII-778 and BRII-732, which are in phase I clinical trials for the treatment of HIV patients; BRII-179 and BRII-835, which are in Phase 2 to evaluate the combination of these two HBV mechanisms for Hepatitis B; BRII-179, a recombinant protein-based HBV immunotherapeutic candidate that is in Phase 1b/2a; BRII-835, which has completed Phase-2 for patients with chronic HBV infection; and Amubarvimab/romlusevimab combination therapy for the treatment of COVID-19. It also develops BRII-296 for the treatment of PPD; BRII-297 for treatment of various depressive disorders; BRII-636, BRII-672, and BRII-693 for the treatment of multi-drug resistant/extensive drug resistant (MDR/XDR) gram-negative infections; and BRII-658 for the treatment of MDR/XDR tuberculosis and non-tuberculosis mycobacteria. The company was incorporated in 2017 and is based in Beijing, China.
Technical Analysis
Mabpharm Limited
―
Clover Biopharmaceuticals Ltd.
―
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H
―
Transcenta Holding Limited
―
AIM Vaccine Co., Ltd. Class H
―
Options Prices
Currently, No data available
---